ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Sends Letter To Grantees To Explain Tighter Funding.

March 16, 2001

In Brief: Thomas Jordan Promoted At Bristol-Myers, Markison To Succeed Him In Oncology Div.

February 28, 1992

In Brief: NCI Still Undecided Over Small Hospital Segment Of CHOP; Multihospital Proposals Review Nov. 14-15

November 2, 1979

Tamoxifen Listed By IARC Report As Carcinogen CTRF Seeks Applicants

March 1, 1996

NCAB Subcommittee Worries About Board’s Makeup

January 19, 1979

Bross Claims New Figures Show High Radiation Risk

February 23, 1979